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Background: Cancer therapy is a challenging research area because side effects often occur in chemo and
radiation therapy. We intend to study a multi-targets and multi-components design that will provide synergistic
results to improve efficiency of cancer therapy.
Methods: We have developed a general methodology, AMFES (Adaptive Multiple FEature Selection), for ranking
and selecting important cancer biomarkers based on SVM (Support Vector Machine) classification. In particular, we
exemplify this method by three datasets: a prostate cancer (three stages), a breast cancer (four subtypes), and
another prostate cancer (normal vs. cancerous). Moreover, we have computed the target networks of these
biomarkers as the signatures of the cancers with additional information (mutual information between biomarkers of
the network). Then, we proposed a robust framework for synergistic therapy design approach which includes varies
existing mechanisms.
Results: These methodologies were applied to three GEO datasets: GSE18655 (three prostate stages), GSE19536
(4 subtypes breast cancers) and GSE21036 (prostate cancer cells and normal cells) shown in. We selected 96
biomarkers for first prostate cancer dataset (three prostate stages), 72 for breast cancer (luminal A vs. luminal B),
68 for breast cancer (basal-like vs. normal-like), and 22 for another prostate cancer (cancerous vs. normal. In
addition, we obtained statistically significant results of mutual information, which demonstrate that the
dependencies among these biomarkers can be positive or negative.
Conclusions: We proposed an efficient feature ranking and selection scheme, AMFES, to select an important subset
from a large number of features for any cancer dataset. Thus, we obtained the signatures of these cancers by
building their target networks. Finally, we proposed a robust framework of synergistic therapy for cancer patients.
Our framework is not only supported by real GEO datasets but also aim to a multi-targets/multi-components drug
design tool, which improves the traditional single target/single component analysis methods. This framework
builds a computational foundation which can provide a clear classification of cancers and lead to an efficient
cancer therapy.
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Cancer therapy is a difficult research area due to its level
of complexity. Lately, the mere superposition of single
drugs is found to generate side-effects and crosstalk with
another drug which may cancel out the final success of
treatments. Thus, current research focuses on measuring
the drug treatments as a whole rather than considering* Correspondence: suchen@cise.ufl.edu
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reproduction in any medium, provided the orthem individually [1,2]. Later, a synergistic concept is
proposed to evaluate the drug treatments [3]. However,
evaluations are still based on cases and do not have a
systematic approach. In [4], a network methodology is
first used to evaluate efficiency of drug treatments. Thus,
Li et al. use a parameter, namely a SS (Synergy Score) to
introduce the topology factor of the network based on
the disease and the drug agent combination [5].
Our approach is first to build a more precise target
network from the selected biomarkers (by AMFES) [6].
Then, we identify the intrinsic properties by computing. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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markers. Our approach is to improve Li’s results by con-
sidering the mutual information in the target network.
And we provide a general framework of synergistic ther-
apy, which may include several different approaches.
Methods
AMFES
The COD (Curse of Dimensionality) has been a major
challenge of microarray data analysis due to the large
number of genes (features) and relatively small number
of samples (patterns). To tackle this problem, many gene
selection methodologies were developed to select only
significant subsets of genes in a microarray dataset.
AMFES selects an optimal subset of genes by training a
SVM with subsets of genes generated adaptively [6].
When AMFES runs a dataset, all samples are ran-
domly divided into a training subset S of samples and a
testing subset T of samples at a heuristic ratio of 5:1. S
is used for ranking and selecting of genes and for con-
structing a classifier out of the selected genes. T is used
for computing test accuracy. When a training subset S is
given, we extract r training-validation pairs from S
according to the heuristic rule r = max (5, (int) (500/n
+0.5)) and n is the number of samples in S. Each pair
randomly divides S into a training component of sam-
ples and a validation component of samples at a ratio of
4:1. The heuristic ratio and rule are chosen based on the
experimental experiences at the balance of time con-
sumption and performance. Basically, AMFES has two
fundamental processes, ranking and selection. We first
explain each process in details and then the integrated
version at the end.
Ranking
The gene ranking process contains a few ranking stages. At
first stage, all genes are ranked by their ranking scores in a
descending order. Then, in the next stage, only the top half
ranked genes are ranked again while the bottom half holds
the current order in the subsequent stage. The same iter-
ation repeats recursively until only three genes are
remained to be ranked again to complete one ranking
process. Assume at a given ranking stage, there are k genes
indexed from 1 to k. To rank these k genes, we follow 4
steps below. (I) We first generate m independent subsets
S1. . . Sm. Each subset Si, i = 1, 2. . . m, has j genes which are
selected randomly and independently from the k genes,
where j = (int) (k/2). (II) Let Ci be the SVM classifier that is
trained on each subset of genes, i = 1, 2. . . m. For each gene
of k genes, we compute the ranking score θm (g) of the gene
g, as equation (1). (III) We use the average weight of the
gene g, the summation of weights of g in m subsets divided
by the number of subsets for which g is randomly selected.
This increases the robustness to represent the trueclassifying ability of the gene g. (IV) Rank k genes in the
descending order by their ranking scores.
θm gð Þ ¼
Xm
i¼1





where I is an indicator function such that Iproposition = 1 if
the proposition is true; otherwise, Iproposition = 0. In other
word, if gene g is randomly selected for the subset Si, it is
denoted as g 2 Si and Iproposition = 1.
We denote the objective function of Ci as
obji v1; v2; . . . ; vsð Þ where v1, v2. . . vs are support vectors
of Ci. The weighti(g) is then defined as the change in the
objective function due to g, i.e.,
weighti gð Þ¼ obji v1; v2; . . .vsð Þobji v gð Þ1 ; v gð Þ2 ; . . . ; v gð Þ3
  
ð2Þ
[6][7,8]. Note that if v is a vector, v(g) is the vector
obtained by dropping gene g from v. Let θm be a vector
comprising the ranking scores derived from the m gene
subsets generated thus far and θm-1 is the vector at the
previous stage. The m value is determined when θm sat-
isfies the equation (3) by adding a gene to an empty sub-




where ||θ|| is understood as the Euclidean norm of vec-
tor θ. The pseudo codes of ranking process are shown in
below.Pseudo codes for ranking process of AMFES
RANK-SUBROUTINE
INPUT: a subset of k genes to be ranked
Generate k artificial genes and put them next to the
original genes
Pick an initial tentative value of m
DO WHILE m does not satisfies equation (3)
FOR each subset Si of m subsets
Randomly select j elements from k genes to form the
subset Si.
Train an SVM to get weighti(g) for each gene in the
subset
ENDFOR
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Compute the average score of the gene from m subsets
ENDFOR
List k genes in descending order by their ranking scores
ENDDO
OUPUT: a ranked k genes
Selection
Ranking artificial features together with original features
has been demonstrated as a useful tool to distinguish
relevant features from irrelevant ones as in [9-11]. In
our selection process, we also use this technique to find
the optimal subset of genes.
Assume a set of genes is given. We generate artificial
genes and rank them together with original ones. After
finishing ranking the set, we assign a gene-index to each
original gene by the proportion of artificial ones that are
ranked above it where the gene-index is the real numerical
value between 0 and 1. Then, we generate a few subset
candidates from which the optimal subset is chosen. Let
p1, p2, be the sequence of subset-indices of the candidates
with p1 < p2 < . . ..where pi = i×0.005 and i= 1,2,. . .200.
Let B(pi) denote the corresponding subset of subset-index
pi, and it contains original genes whose indices are smaller
than or equal to pi. Then, we train a SVM on every B(pi),
and compute its validation accuracy v(pi).
We stop at the first pk at which v(pk) ≥ vbaseline and v
(pk) ≥ v(pl) for k ≤ l ≤ k+10, where vbaseline is the valid-
ation accuracy rate of the SVM trained on the baseline,
i.e., the case in which all features are involved in train-
ing. The final result, B(pk), is then the optimal subset for
the given set of genes. The pseudo codes for selection
process of AMFES are listed below.
Pseudo codes for selection process of AMFES
SELECTION-SUBROUTINE
INPUT: a few subsets with their validation accuracies,
av(pi)
Compute the validation accuracy of all genes, vbaseline.
FOR each subset given
IF v(pk) ≥ vbaseline and v(pk) ≥ v(pl) for k ≤ l ≤ k+10
THEN




The ranking and selection processes from previous sec-
tions are for one training- validation pair. To increase
the reliability of validation, we generate r pairs to find
the optimal subset. We calculate the validation accuracy
of the qth pair for all pq-i subsets where q denotes pair-
index and i denotes the subset-index. Then, we compute
av(pi), the average of v(pq-i) over r training-validation
pairs and perform the subset search as explained in se-
lection section on av(pi) to find the optimal pi, denoted
as p*.However, p* does not correspond to a unique sub-
set, since each pair has its own B(p*) and they can be all
different. Thus, we adopt all samples of S as training
samples in order to find a unique subset. We generate
artificial genes and rank them together with original
genes. Finally, we select the original genes whose indices
are smaller than or equal to the p* as the genes we select
for S. The integrated version of process is shown below.
In the pseudo codes below, the AMFES-ALGORITHM
represents the integrated version of the whole process
while RANK-SUBROUTINE represents the ranking
process and SELECTION-SUBROUTINE represents the
selection process.Pseudo codes for integrated version of AMFES
AMFES ALGORITHM-Integrated Version
INPUT: a dataset
Divide a dataset into train samples and test samples.
Divide the train samples into r training-validation
components pairs
FOR each pair of r train-validation components pairs
Generate 200 candidate subsets pq-i
FOR each subset of 200 subsets
CALL RANK subroutine to rank each subset.
Assign each original gene a gene-index
Train each subset on an SVM and compute




FOR each subset of 200 subsets
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from r pairs.
END FOR
CALL SELECTION subroutine to search for the
optimal subset by its average validation rate and
denotes it as p*
CALL RANK subroutine to rank original genes again
and select original genes which belong to the subset B
(p*).
OUPUT: an optimal subset of genes B(p*)
Mutual information
Mutual information has been used to measure the de-
pendency between two random variables based on the
probability of them. If two random variables X and Y,
the mutual information of X and Y, I(X; Y), can be
expressed as these equivalent equations [12]:
I X;Yð Þ ¼ H Xð Þ  H X Yj Þ ð4Þð
¼ H Yð Þ  H Y Xj Þ ð5Þð
¼ H Xð Þ þ H Yð Þ  H X;Yð Þ ð6Þ
where H(X), H(Y) denote marginal entropies, H(X|Y) and
H(Y|X) denote conditional entropies and H(X,Y) denotes
joint entropy of the X and Y. To compute entropy, the
probability distribution functions of the random variables
are required to be calculated first. Because gene expres-
sions are usually continuous numbers, we used the kernel
estimation to calculate the probability distribution [13].
Assume the two random variables X and Y are con-
tinuous numbers. The mutual information is defined as
[12]:
I X;Yð Þ ¼
Z Z
f x; yð Þ log f x; yð Þ
f xð Þf yð Þ
 
dxdy ð7Þ
where f(x,y) denotes the joint probability distribution, and
f(x) and f(y) denote marginal probability distribution of X
and Y. By using the Gaussian kernel estimation, the f(x, y),
f(x) and f(y) can be further represented as equations below
[14]:







xxuð Þ2þ yy2uð Þð Þ ð8Þ





p e 12h2 xyuð Þ2 ; ð9Þ
where M represents the number of samples for both Xand Y, u is index of samples u ¼ 1; 2; . . .M; and h is a par-
ameter controlling the width of the kernels. Thus, the mu-
tual information I X;Yð Þ can then be represented as:
























where both w, u are indices of samples w; u ¼ 1; 2; . . .M.
Computation of pairwise genes of a microarray dataset
usually involves nested loops calculation which takes a
dramatic amount of time. Assume a dataset has N genes
and each gene has M samples. To calculate the pairwise
mutual information values, the computation usually first
finds the kernel distance between any two samples for a
given gene. Then, the same process goes through every
pair of genes in the dataset. In order to be computation
efficient, two improvements are applied [13]. The first
one is to calculate the marginal probability of each gene
in advance and use it repeatedly during the process [13]
[15].The second improvement is to move the summation
of each sample pair for a given gene to the most outer
for-loop rather than inside a nested for-loop for every
pairwise gene. As a result, the kernel distance between
two samples is only calculated twice instead N times
which saves a lot of computation time. LNO (Loops
Nest Optimization) which changes the order of nested
loops is a common time-saving technique in computer
science field [16].
Target network
The effect of drugs with multiple components should be
viewed as a whole rather than a superposition of individ-
ual components [1] [2]. Thus, a synergic concept is
formed and considered as an efficient manner to design
a drug [3]. In [17], mathematical models are used to
measure the effect generated by the multiple compo-
nents. However, it does not consider practical situation
such as crosstalk between pathways. A network ap-
proach starts to be used to analyze the interactions
among multiple components [4]. Initiated by work in
[4], another system biological methodology, NIMS (Net-
work-target-based Identification of Multicomponent
Synergy) is proposed to measure the effect of drug agent
pairs depending on their gene expression data [5]. NIMS
focuses on ranking the drug agent pairs of Chinese
Medicine components by their SS.
In [5], it assumes that a drug component is denoted as
a drug agent and with which a set of genes associated are
denoted as agent genes of the drug agent. For a given dis-
ease, assume there are N drug agents where N =1, 2. . .n.
Initially, NIMS randomly chooses two drug agents from
N, A1, and A2, and builds a background target network
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calculates TS (Topology Score) of the graph by applying
the PCA (Principle Component Analysis) to form a IP
value which is integrated by betweenness, closeness and
a variant of Eigenvalues PageRank [18]. The TS is used to
evaluate the topology significance of the target network





















where IP1 and IP2 denote IP values for drug agent A1
agent and A2. Min(di,j) denotes minimum shortest path
from gene i of A1 to all genes of A2 and min(dj,i) denotes
the one from gene j of A1 to all genes of A2.
NIMS define another term, AS (Agent Score), to evalu-
ate the similarity of a disease phenotype for a drug agent.
For a given drug agent, if one of its agent genes has a
phenotype record in the OMIM (Online Mendelian In-
heritance in Man) database, the drug agent has that
phenotype as one of its phenotype. The similarity score
of a drug agent pair is defined as the cosine value of the







where Pi,j denotes similarity score of ith phenotype of A1
and jth phenotype of A2 and M denotes the total number
of phenotypes.
The SS of the pair is then defined as the product of TS
and AS. NIMS calculates SS for all possible drug agent
pairs for a disease and then can find potential drug agent
pairs after ranking them by SS.Table 1 Descriptions of 3 datasets: GSE18655 (prostate cance
cancer)
Prostate Cancer (GSE18655)
Number of Biomarkers 502
Type of Biomarkers RNAs
Number of Samples 139
Variation of Samples Grade1(38), Grade2(90),
Grade3(11)Results
MIROARRAY data description
We made a brief description of these three datasets in
Table 1. It listed the number of biomarkers, types of bio-
markers, number of samples and variation of samples
used.
The prostate cancer dataset with RNA biomarkers
In order to give a better prognosis, pathologists have
used a cancer stage to measure cell tissues and tumors’
aggressions as an indicator for doctors to choose a suit-
able treatment. The most widely used cancer staging sys-
tem is TNM (Tumor, Node, and Metastasis) system [20].
Depending on levels of differentiation between normal
and tumor cells, a different histologic grade is given.
Tumors with grade 1 indicate almost normal tissues,
with grade 2 indicating somewhat normal tissues and
with grade 3 indicating tissues far away from normal
conditions. Although most of cancers can be adapted to
TNM grading system, some specific cancers require add-
itional grading systems for pathologists to better inter-
pret tumors.
The Gleason Grading System is especially used for pros-
tate cancers and a GS (Gleason Score) is given based on
cellular contents and tissues of cancer biopsies from
patients. The higher the GS are, the worse the prognoses
are. The prostate cancer dataset, GSE18655, includes 139
patients with 502 molecular markers, RNAs [21]. In [21], it
showed that prostate tumors with gene fusions, TMPRSS2:
ERG T1/E,4 have higher risk of recurrences than tumors
without the gene fusions. 139 samples were prostate fresh-
frozen tumor tissues of patients after a radical prostatec-
tomy surgery. All samples were taken from the patients’
prostates at the time of prostatectomy and liquid nitrogen
was used to freeze middle sections of prostates at extreme
low temperature. Among these patients, 38 patient samples
have GS 5–6 corresponding to histologic grade 1, 90 sam-
ples have GS 7 corresponding to histologic grade 2 and 11
samples have GS 8–9 corresponding to histologic grade 3.
The platform used for the datasets is GPL5858, DASL
(cDNA-mediated, annealing, selection, extension and
ligation) Human Cancer Panel by Gene manufactured by
Illumina. The FDR (false discovery rate) of all RNAs
expressions in the microarray is less than 5%.r), GSE19536 (breast cancer) and GSE21036 (prostate




Luminal A ( 41), Luminal B (12),
Basal-like (15), Normal-like(10)
Cancerous (114), Normal(28)
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The miRNAs have strong correlation with some cellular
processes, such as proliferation, which has been used as
a breast cancer dataset [22]. It has 799 miRNAs and 101
patients’ samples. Differential expressions of miRNAs
indicated different level of proliferations corresponding
to 6 intrinsic breast cancer subtypes: luminal A, luminal
B, basal-like, normal-like, and ERBB2. The original data-
set has 101 samples and among them, 41 samples are lu-
minal A, 15 samples are basal-like, 10 samples are
normal-like, 12 samples are luminal B, 17 samples are
ERBB2, 2 samples have T35 mutation status, another
sample has T35 wide type mutation and 3 samples are
not classified. GSE19536 was represented in two plat-
forms GPL8227, an Agilient-09118 Human miRNA
microarray 2.0 G4470B (miRNA ID version) and the
GPL6480, an Agilent-014850 whole Human Genome
Microarray 4x44k G4112F (Probe Name). For this paper,
we only used the expressions from GPL8227.
Prostate cancer dataset of cancerous and normal samples
with miRNA biomarkers
The CNAs (Copy Number Alterations) of some genes
may associate with growth of prostate cancers [23]. In
addition, some changes are discovered in mutations of
fusion gene, mRNA expressions and pathways in a ma-
jority of primary prostate samples. The analysis was ap-
plied to four platforms and consists of 3 subseries,
GSE21034, GSE21035 and GSE21036 [23]. For this
paper, we only use the GSE 21036 for analysis. The
microarray dataset has 142 samples which include 114
primary prostate cancer samples and 28 normal cells
samples. The platform is Agilent-019118 Human miRNA
Microarray 2.0 G4470B (miRNA ID version).
Results of AMFES
We employ the AMFES on the prostate cancer
(GSE18655), breast cancer (GSE19536) and another pros-
tate cancer (GSE21036) datasets. Consequently, for
GSE18655, AMFES selects 96 biomarkers. The classifica-
tion is performed in two steps. The first step performs clas-
sification between grade1 and above samples and it selects
93 biomarkers. At the second step, AMFES classifies be-
tween grade2 and grade3 samples and it selects 3 biomar-
kers. Thus, we can assume that these 96 biomarkers can
classify among grade1, grade2 and grade3 samples [6]. For








Variation of Samples Grade1, Grade2, Grade3 Luminalsteps. At the first step, AMFES classify between luminal
and non-luminal types samples and it selects 47 biomar-
kers [6]. At the second step, AMFES further classifies lu-
minal samples into luminal A and luminal B and selects 27
biomarkers. For the non-luminal samples, AMFES also
classifies them into basal-like and normal-like samples and
selects 25 biomarkers [6]. After removing duplicate
biomarkers, AMFES has 72 (47+27-2(duplicated)) for
classifying luminal samples and 68 (47+25-4(duplicated))
for classifying non-luminal ones [6]. For GSE21036,
AMFES simply selects 22 biomarkers for classifying can-
cerous and normal samples. Table 2. shows the number
of selected genes. The complete lists of these biomarkers
can be found in Additional file 1 GSE18655_96_Biomar-
kers.xlsx, Additional file 2 GSE19536_72_Biomarkers.xlsx,
Additional file 3 GSE19536_68_Biomarkers.xlsx, and
Additional file 4 GSE21036_22_Biomakers.xlsx.
We then apply the MI calculation described in the Mu-
tual Information section on 96 biomarkers for GSE18655
and represent the pairwise MI values of grade 1, grade 2
and grade 3 samples in three 96*96 matrixes which can
be found in Additional file 5 GSE18655 Grade1 MI.xlsx,
Additional file 6 GSE18655 Grade2 MI.xlsx and Add-
itional file 7 GSE18655 Grade3 MI.xlsx. We also repre-
sent the four MI matrixes of 72 and 68 biomarkers for
GSE19536 in Additional file 8 GSE19536 Luminal-A MI.
xlsx, Additional file 9 GSE19536 Luminal-B MI.xlsx,
Additional file 10 GSE19536 Basal-Like MI.xlsx, and
Additional file 11 GSE19536 Normal-Like MI.xlsx. The
two MI matrixes for GSE21036 are in Additional file 12
GSE21036 Cancer MI.xlsx, Additional file 13 GSE21036
Normal MI.xlsx.
We analyze these MI matrixes and list differences be-
tween them under different conditions in Table 3. For a
given matrix, the first column in Table 3 denotes the
mean value; the second column denotes the standard de-
viation; the third column shows the number of positive
values in the matrix; the fourth column shows the num-
ber of negative values; the sixth column shows the mini-
mum value and the seventh column displays the
maximum. In the fifth column, we compare MI matrixes
under two different conditions such as luminal A vs. lu-
minal B. If the signs of two entries at the same position
in these two matrixes are different, we count it as one
sign difference. The fifth column denotes the number of
sign differences of the samples compared. We employ
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GSE18655_grade1 0.00024 0.0015 6298 2918 N/A −0.0011 0.0858
GSE18655_grade2 0.00020 0.0017 6468 2748 −0.0018 0.0949
GSE18655_grade3 0.0004 0.0021 6650 2566 −0.0029 0.0582
GSE19536_A(72) 0.00036 0.0022 3912 1272 2052 −0.0010 0.1293
GSE19536_B(72) 0.00053 0.0040 3388 1796 −0.0022 0.2279
GSE19536_BasalLike(68) 0.0017 0.0056 3491 998 1217 −0.0033 0.1648
GSE19536_NormalLike(68) 0.0056 0.008 4200 420 −0.002 0.1279
GSE21036_cancer 0.0165 0.0212 10 474 56 −0.002 0.1446
GSE21036_norm 0.0086 0.0146 46 438 −0.0015 0.1565
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mal for GSE21036. To visualize the differences, we dis-
play the histograms of MI values of grade1s, grade2s and
grade3s in Figure 1. Figure 2 shows the histograms for
luminal As versus luminal Bs. Figure 3 shows basal-likes
versus normal-likes and Figure 4 shows the cancerous
versus normals.
For the fifth column of comparison of GSE18655, since
there are three types prostate, they cannot be fairly com-
pared, so we skipped the process for it. In addition, be-
cause there are many MI entries for all histograms, we

















Figure 1 Comparison of 96 MI of grade1, grade2 and grade3 samplesResults of calculating mutual information
The statistic results of calculating mutual information
are shown in Table 3 at the end of this paper.Synergistic therapy
Based on the interpretation of the network [4,5], we pro-
posed a framework that can help to elucidate the under-
lying interactions between multi-target biomarkers and
multi-component drug agents. The framework consists of
three parts: selecting biomarkers of a complex disease such





















Figure 2 Comparison of 72 MI of luminal A and luminal B samples.
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to provide a personalized and synergistic therapy plan.
From the GEO datasets of cancers, we have discovered
the genetic model of each cancer, called signature of that
particular cancer. Among different cancers, their signatures






























































Figure 3 Comparison of 68 MI of basal-like and normal-like samples.to different biomarkers in Additional file 1 GSE18655_96_
Biomarkers.xlsx, Additional file 2 GSE19536_72_Biomar-
kers.xlsx, Additional file 3 GSE19536_68_Biomarkers.xlsx,
and Additional file 4 GSE21036_22_Biomakers.xlsx.. For
these different signatures, we would discover various syner-


















































































Figure 4 Comparison of 22 MI of prostate cancerous and normal samples.
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plan of a patient A. By collecting his/her bodily data such
as saliva, blood samples, we first obtain the correspond-
ing microarray dataset of patient A and apply it to the
genetic model as shown in Figure 5.
A complete synergistic therapy should be able to select
small subset of biomarkers and correlate them with drug
agents in a multi-target multi-components network ap-
proach as shown in Figure 6. In Figure 6, a disease associ-
ates with several biomarkers such as RNAs, miRNAs or
proteins denoted by R1, R2, R3, R4 and R5 which are the
regulators for operons O1, O2, and O3. An operon is a
basic unit of DNAs and formed by a group of genes con-
trolled by a gene regulator. These operons initiateFigure 5 Diagram of detailed process of building the genetic model.molecular mechanisms as promoters. The gene regulators
can enable organs to regulate other genes either by induc-
tion or repression. For each target biomarker, it may have
a list of pharmacons used as enzyme inhibitors. Tradition-
ally, pharmacons are referred to biological active sub-
stances which are not limited to drug agents only. For
example, the herbal extractions whose ingredients have a
promising anti-AD (Alzheimer’s Disease) effect can be
used as pharmacons [24]. Meanwhile, pharmacons
denoted by D1, D2, and D3, have effects for some target
biomarkers. For example, D1 affects target biomarker R3,
D2 affects target biomarker R5 and D3 affects biomarker
R1. Compared with drug agent pair methodology [5],



















Figure 6 Relationships between biomarkers, pharmacons and operons where R1, R2, R3, R4 and R5 denote 5 biomarkers. Among all the
biomarkers, R2, R3 and R5 are regulators.
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component drug agents.Discussion
Among the MI values obtained, we see positive values
and negative values. The positive value can represent the
attractions among the biomarkers while the negative
may represent the repulsion among the biomarkers,
which matches the concept of Yin-Yang in TCM (Trad-
itional Chinese Medicine). From these results, we
observed that there is minimal difference of mutual in-
formation values between cancer stages. However, the
difference of mean MI value of the prostate cancer ver-
sus normal cells is move obvious. The mean MI value of
the last prostate cancer cell is approximately twice that
of normal cells. This may be intriguing for medical
people for further investigations.Conclusions
We have presented a comprehensive approach to diag-
nosis and therapy of complex diseases, such as cancer. A
complete procedure is proposed for clinical application
to cancer patients. While the genetic model provides a
standard framework to design synergistic therapy, the
actual plan for individual patient is personalized and
flexible. With careful monitoring, physicians may adap-
tively change or modify the therapy plan. Much furtheranalysis of this framework in clinical settings should be
experimented.
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